PTC Therapeutics (PTCT) Insider Gregory Buys $310K of Stock

Neil Gregory Almstead, the Chief Technical Officer at PTC Therapeutics, Inc. (NasdaqGS:PTCT), made a significant move by purchasing 8,130 shares of the company at an average price of $38.10 each. The transaction, which took place on June 26, 2026, was valued at approximately $309,753. This insider activity wasn't part of a pre-planned trading program.

Insider Buying and Selling at PTC Therapeutics, Inc.

Almstead's recent acquisition wasn't his only transaction. On the same day, he also sold 8,130 shares at $85.26 each as part of a planned trade. Additionally, Almstead engaged in several transactions on June 25, 2026, buying and selling shares at different prices, with some trades being planned and others not.

PTC Therapeutics, Inc. Stock Up 33.7%

Shares of PTC Therapeutics traded near $81.57 on Wednesday. The company has a market capitalization of approximately $7 billion and a forward P/E ratio of 30.3, indicating investor expectations for future earnings. PTC Therapeutics' shares have ranged from a 52-week low of $43.18 to a high of $87.50. The stock's 50-day moving average is $72.22, while the 200-day moving average stands at $70.94. The company maintains a current ratio of 2.44 and a quick ratio of 2.29, reflecting its ability to cover short-term liabilities.

Analysts Set New Price Targets

Analysts are keeping a close eye on PTC Therapeutics. On June 9, 2026, Citigroup assumed coverage with a buy rating and set a price target of $108. Earlier, Jefferies upgraded its rating to buy with an $85 target on May 27, 2026. Meanwhile, TD Cowen and Wells Fargo also issued buy ratings, with targets of $90 and $95, respectively.

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company based in Warren, New Jersey. It focuses on discovering, developing, and commercializing medicines for rare disorders affecting children and adults. The company offers treatments for Duchenne muscular dystrophy, AADC deficiency, and spinal muscular atrophy. PTC Therapeutics also has a robust pipeline, including treatments for phenylketonuria and Huntington's disease. The company collaborates with several partners, including F. Hoffman-La Roche and Novartis Pharmaceuticals.

Bottom Line

Neil Gregory Almstead's recent insider purchase of PTC Therapeutics shares is noteworthy, especially given the stock's recent trading activity and analyst interest. Investors often watch insider transactions for potential signals, though such trades do not always indicate future stock performance. As a reminder, insider trading reports are typically disclosed after the fact, providing a backward-looking view.